ILMN - Illumina, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
San Diego,
United States
Type: Equity
ILMN price evolution
ILMN
| (in millions $) | 31 Jan 2024 | 2 Aug 2023 | 2 May 2023 | 1 Feb 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1048 | $927 | $1553 | $1494 |
| Short term investments | $6 | $6 | $6 | $24 |
| Net receivables | $734 | $758 | $682 | $688 |
| Inventory | $587 | $617 | $586 | $568 |
| Total current assets | $2609 | $3223 | $3172 | $3561 |
| Long term investments | ||||
| Property, plant & equipment | $1551 | $1707 | $1740 | $1744 |
| Goodwill & intangible assets | $5538 | $5556 | $6427 | $6476 |
| Total noncurrent assets | $7502 | $7616 | $8551 | $8639 |
| Total investments | $6 | $6 | $6 | $24 |
| Total assets | $10111 | $11774 | $11811 | $12252 |
| Current liabilities | ||||
| Accounts payable | $245 | $244 | $242 | $293 |
| Deferred revenue | ||||
| Short long term debt | $750 | $749 | ||
| Total current liabilities | $1570 | $2303 | $2230 | $2773 |
| Long term debt | $2176 | $1488 | $1487 | $1487 |
| Total noncurrent liabilities | $2796 | $2742 | $2916 | $2888 |
| Total debt | $2176 | $2187 | $2964 | $2983 |
| Total liabilities | $4366 | $5219 | $5118 | $5653 |
| Shareholders' equity | ||||
| Retained earnings | -$19 | $911 | $1145 | $1142 |
| Other shareholder equity | -$1 | $12 | -$1 | $3 |
| Total shareholder equity | $5745 | $5898 | $6555 | $6693 |
| (in millions $) | 31 Jan 2024 | 1 Feb 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1048 | $2011 | $1232 | $1810 |
| Short term investments | $6 | $26 | $107 | $1662 |
| Net receivables | $734 | $688 | $648 | $487 |
| Inventory | $587 | $568 | $431 | $372 |
| Total current assets | $2609 | $3561 | $2713 | $4483 |
| Long term investments | $418 | |||
| Property, plant & equipment | $1551 | $1744 | $1696 | $1454 |
| Goodwill & intangible assets | $5538 | $6524 | $10363 | $1039 |
| Total noncurrent assets | $7502 | $8691 | $12504 | $3102 |
| Total investments | $6 | $26 | $107 | $1662 |
| Total assets | $10111 | $12252 | $15217 | $7585 |
| Current liabilities | ||||
| Accounts payable | $245 | $293 | $332 | $192 |
| Deferred revenue | ||||
| Short long term debt | $1248 | $511 | ||
| Total current liabilities | $1570 | $2773 | $1093 | $1244 |
| Long term debt | $2176 | $1487 | $2469 | $1344 |
| Total noncurrent liabilities | $2796 | $2880 | $3384 | $1647 |
| Total debt | $2176 | $3479 | $2469 | $1855 |
| Total liabilities | $4366 | $5653 | $4477 | $2891 |
| Shareholders' equity | ||||
| Retained earnings | -$19 | $1142 | $5485 | $4723 |
| Other shareholder equity | -$1 | $3 | $17 | $2 |
| Total shareholder equity | $5745 | $6599 | $10740 | $4694 |
| (in millions $) | 31 Jan 2024 | 2 Aug 2023 | 2 May 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1176 | $1087 | $1087 | |
| Cost of revenue | $432 | |||
| Gross Profit | $732 | $655 | $655 | |
| Operating activities | ||||
| Research & development | $341 | |||
| Selling, general & administrative | $378 | |||
| Total operating expenses | $778 | $718 | $719 | |
| Operating income | -$64 | |||
| Income from continuing operations | ||||
| EBIT | -$58 | |||
| Income tax expense | $145 | -$81 | -$81 | |
| Interest expense | -$3 | -$17 | $20 | |
| Net income | ||||
| Net income | -$234 | $3 | $3 | |
| Income (for common shares) | $3 | |||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 2 Feb 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4504 | $4584 | $3239 | |
| Cost of revenue | $1760 | $1612 | $1036 | |
| Gross Profit | $2744 | $2972 | $2203 | |
| Operating activities | ||||
| Research & development | $1354 | $1321 | $682 | |
| Selling, general & administrative | $1612 | $1297 | $941 | |
| Total operating expenses | $3813 | $7151 | $1623 | |
| Operating income | -$1069 | -$4179 | $580 | |
| Income from continuing operations | ||||
| EBIT | -$1040 | -$4310 | $905 | |
| Income tax expense | $44 | $68 | $200 | |
| Interest expense | $77 | $26 | $49 | |
| Net income | ||||
| Net income | -$1161 | -$4404 | $656 | |
| Income (for common shares) | -$1161 | -$4404 | $656 | |
| (in millions $) | 31 Dec 2023 | 2 Aug 2023 | 2 May 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$175 | $3 | ||
| Operating activities | ||||
| Depreciation | $109 | $107 | ||
| Business acquisitions & disposals | -$29 | |||
| Stock-based compensation | $94 | $93 | ||
| Total cash flows from operations | $224 | $10 | ||
| Investing activities | ||||
| Capital expenditures | -$51 | -$52 | ||
| Investments | $13 | -$3 | ||
| Total cash flows from investing | -$85 | -$93 | -$56 | -$56 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $37 | |||
| Net borrowings | -$501 | |||
| Total cash flows from financing | -$27 | -$476 | -$473 | -$473 |
| Effect of exchange rate | $9 | -$4 | $2 | $2 |
| Change in cash and equivalents | $121 | -$458 | -$517 | -$517 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1161 | -$4404 | $762 | $656 |
| Operating activities | ||||
| Depreciation | $432 | $394 | $251 | $187 |
| Business acquisitions & disposals | -$29 | -$85 | -$2392 | -$230 |
| Stock-based compensation | $380 | $366 | $754 | $194 |
| Total cash flows from operations | $478 | $392 | $545 | $1080 |
| Investing activities | ||||
| Capital expenditures | -$195 | -$286 | -$208 | -$189 |
| Investments | -$6 | -$40 | $1233 | -$135 |
| Total cash flows from investing | -$231 | -$591 | -$1069 | -$554 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $67 | $63 | $60 | -$675 |
| Net borrowings | -$1236 | $991 | $471 | |
| Total cash flows from financing | -$1210 | $1000 | -$51 | -$766 |
| Effect of exchange rate | -$22 | -$3 | $8 | |
| Change in cash and equivalents | -$963 | $779 | -$578 | -$232 |
News
Fundamentals
| Market cap | $19.79B |
|---|---|
| Enterprise value | $20.92B |
| Shares outstanding | 159.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 3.44 |
| Book/Share | 36.14 |
| Cash/Share | 6.59 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.76 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.66 |
| Quick ratio | 1.29 |